Miller Deborah Ann 4
4 · Nuvalent, Inc. · Filed Mar 2, 2026
Research Summary
AI-generated summary of this filing
Nuvalent (NUVL) CLO Deborah Miller Exercises Options and Sells Shares
What Happened
- Deborah Ann Miller, Chief Legal Officer of Nuvalent, exercised options to acquire 5,500 shares at $6.89 per share (cost $37,895) on 2026-02-26 and, on the same day, sold a total of 5,500 shares in open-market transactions for combined proceeds of approximately $566,788 (sales of 2,698 shares at $102.64, 2,602 shares at $103.41, and 200 shares at $103.96). The Form 4 also shows a simultaneous derivative disposition of 5,500 shares at $0.00 (reported as a derivative conversion).
- These actions are typically consistent with a cashless exercise (exercise followed by immediate sale of the acquired shares), but the filing does not state the insider’s motivation.
Key Details
- Transaction date: February 26, 2026; Form 4 filed March 2, 2026 (timely).
- Exercise: 5,500 shares at $6.89 (total $37,895).
- Open-market sales: 2,698 shares @ $102.64 ($276,923); 2,602 shares @ $103.41 ($269,073); 200 shares @ $103.96 ($20,792). Total sale proceeds ≈ $566,788.
- Derivative entry: 5,500 shares disposed at $0.00 — reported as a conversion/derivative settlement on the form.
- Footnotes: Transactions were effected under a Rule 10b5-1 trading plan adopted November 18, 2024; reported sale prices are weighted averages with ranges across multiple trades. The exercised option shares were fully vested.
- Shares owned after the transactions: not specified in the supplied filing.
Context
- Because the trades were made under a pre-established 10b5-1 plan and involved exercising options then selling the resulting shares the same day, this appears routine rather than an unsolicited market-timing signal. Form 4s are informational — they report transactions but do not explain the insider’s reasons.
Insider Transaction Report
Form 4
Nuvalent, Inc.NUVL
Miller Deborah Ann
Chief Legal Officer
Transactions
- Exercise/Conversion
Class A Common Stock
[F1]2026-02-26$6.89/sh+5,500$37,895→ 65,134 total - Sale
Class A Common Stock
[F1][F2]2026-02-26$102.64/sh−2,698$276,923→ 62,436 total - Sale
Class A Common Stock
[F1][F3]2026-02-26$103.41/sh−2,602$269,073→ 59,834 total - Sale
Class A Common Stock
[F1]2026-02-26$103.96/sh−200$20,792→ 59,634 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F4]2026-02-26−5,500→ 89,108 totalExercise: $6.89Exp: 2031-04-29→ Class A Common Stock (5,500 underlying)
Footnotes (4)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2024.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.96 to $102.95, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.96 to $103.95, inclusive.
- [F4]The shares underlying this option are fully vested.
Signature
/s/ Nathan McConarty, attorney-in-fact|2026-03-02